+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Targeted Protein Degradation Technologies

  • Book

  • June 2025
  • Elsevier Science and Technology
  • ID: 6035842

Targeted Protein Degradation Technologies provides a thorough overview of targeted protein degradation from the latest developments in the field to potential therapeutic applications. The book begins with an introduction to the mechanisms of protein degradation followed by a section covering both protease-mediate degradation and lysosome-mediate degradation. A range of cutting-edge technologies are covered, including PROTAC, AbTAC, molecular glues, hydrophobic tagging, LYTAC, GlueTAC and AUTAC. Degraders of specific proteins are then investigated, including signal transduction receptors, membrane proteins, and transcription factor degraders. The book closes with a section on the clinical applications of targeted protein degradation and a look at future perspectives. It is a useful resource to those in the fields of molecular biology, cell biology, and related areas working with protein degradation and the development of therapeutic technologies in this arena.

Table of Contents

Part 1: Introduction 1. Mechanisms of protein degradation 2. Overview of targeted protein degradation Part 2: Summary of targeted protein degradation 3. Protease-mediate degradation 4. PROTAC 5. AbTAC 6.? Molecular glues 7.? Hydrophobic tagging technology 8. Lysosome-mediate degradation 9. LYTACs 10.? Bispecific Apt amer Chimera (BIAC) 11. ?GlueTAC 12. AUTACs 13. ATTECs 14. AUTOTAC Part 3:? Degradation of Proteins?of Interest 15. Degraders of signal transduction receptors 16. Degraders of membrane-associated proteins 17. Degraders of cell cycle- and anti-apoptosis-related proteins 18.? Degraders of proteins in epigenetic regulation 19. Degraders of proteins involved in transcription nuclear hormone receptors 20. Transcription factor degraders Part 4: Clinical applications of targeted protein degradation 21. Clinical development of protein degraders

Authors

Jiangjiang Qin Professor of Cancer Pharmacology and Drug Discovery, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, China. Dr. Jiangjiang Qin is currently a Professor of Cancer Pharmacology and Drug Discovery at the Institute of Basic Medicine and Cancer (IBMC), and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital). He received his PhD in Biomedical Engineering with the highest honor from Shanghai Jiao Tong University, China before completing postdoctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC). Following this he was appointed as Senior Research Associate at the university. Dr. Qin's research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. He has published more than 120 research papers and reviews. He is an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an editorial board member of more than 10 scientific journals. Xin Luan Professor, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine (SHUTCM), Shanghai, Xuhui District, China. Dr. Xin Luan received his B.Sc. in Pharmaceutics from China Pharmaceutical University (2011) and was awarded his PhD degree in Pharmacology at Shanghai Jiao Tong University (2016). He subsequently worked for two years as post-doctor at the University of Michigan under the guidance of Professor Duxin Sun. In 2018, he joined Shanghai University of Traditional Chinese Medicine (SHUTCM), and is currently appointed as a professor. He is currently working on anti-tumor pharmacology and delivery systems of natural products. Dr. Luan has published more than 60 research papers and reviews. Weidong Zhang Professor, Shanghai University of Traditional Chinese Medicine and Second Military Medical University, Shanghai, China. Dr. Weidong Zhang obtained his BSc and Master degree in Natural Medicinal Chemistry from the Second Military Medical University in 1988 and 1991, respectively. He received his PhD in Natural Medicinal Chemistry from the Shanghai Institute of Pharmaceutical Industry (1998), under the supervision of Professor HuiTing Li. He is currently a professor of the Shanghai University of Traditional Chinese Medicine and Second Military Medical University. His research mainly focuses on Chinese medicine formulas, isolation, structural identification and modification, total synthesis, and structure-activity relationships of bioactive natural products. Dr. Zhang has published more than 500 peer-reviewed research papers and reviews.